SMARTHealth Diabetes
BehavioralSMARTHealth Diabetes is an interactive mobile health platform to promote improved self-management for people with T2DM.
NCT Number: NCT02726100
It's a community-based parallel-arm cluster Randomized Controlled Trial (RCT). An interactive mobile health management system will be developed to support lay family health promoters and healthcare staff to improve clinical outcomes for family members with Type 2 Diabetes Mellitus (T2DM). 2,000 participants from 80 sites will be chosen from urban (40 communities) and rural (40 villages) settings in Shijiazhuang City, Hebei Province.
Looking for future studies?
Notify Me40 year–75 year
All sexes
Interventional
Not applicable
Center of Disease Control and Prevention, Luquan, Shijiazhuang, Hebei, China
Study design and Settings:
Cluster randomised controlled trial involving 80 sites (40 communities in urban Shijiazhuang and 40 villages in rural Shijiazhuang) and 2,000 people with T2DM.
Hypothesis:
An interactive mobile health management system can support lay family health promoters (FHP) and healthcare staff to improve clinical outcomes for family members with T2DM
Intervention:
SMARTHealth Diabetes is an interactive mobile health platform to promote improved self-management for people with T2DM. It comprises the following core features:
Community eligibility:
Statistical power:
80 clusters and a mean community cluster size of 25 participants (2,000 total) will provide 90% power to detect an absolute improvement of 10% in the primary outcome. This assumes 20% of people in the control arm will achieve ≥2 'ABC' diabetes goals ((HbA1C<7%; Blood Pressure <140/80 mmHg, LDL cholesterol <100mg/dl or 2.6mmol/L) at end of study; an intra-class correlation coefficient of 0.05, a 20% loss to follow-up, and a 2-sided significance level of 0.05. This translates to a mean reduction of 0.35% for HbA1C, 0.14 mmol/L for LDL cholesterol and 3.4mmHg for systolic BP. Primary analyses will be conducted at the patient level. Secondary analyses will be conducted at the cluster level. Sub-group analyses will be conducted at the community level (based on size and health service characteristics) and patient level (based on demographic factors (co-habitation with FHP) and clinical factors (control rate of 'ABC' risk factors at baseline).
Significance:
The Chinese government has placed prevention and treatment of diabetes as one of 11 National Basic Public Health Services. Despite great promise for mobile health (mHealth) interventions to improve access to effective healthcare, there remains uncertainty about how this can be successfully achieved. These uncertainties pose substantial dilemmas for health system planners. The findings are likely to inform policy on a scalable strategy to overcome sub-optimal access to effective health care in China.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Psychologically or physically unable to participate the trials.
SMARTHealth Diabetes is an interactive mobile health platform to promote improved self-management for people with T2DM.
Time frame: 24 months
The proportion of patients achieving at least two "ABC" goals defined as any two of the following: HbA1c <7.0%, blood pressure (BP) <140/80mmHg and LDL cholesterol <100mg/dl or 2.6mmol/L) at 24 months
Time frame: 24 months
The proportion of patients achieving HbA1c <7.0% at 24 months
Time frame: 24 months
The proportion of patients achieving blood pressure (BP) <140/80mmHg at 24 months
Time frame: 24 months
The proportion of patients achieving LDL cholesterol <100mg/dl or 2.6mmol/L at 24 months
Time frame: 24 months
The proportion of patients achieving FPG<7.0 mmol/L at 24 months
Time frame: 24 months
Mean change in HbA1c level from baseline to 24 months
Time frame: 24 months
Mean changes in systolic and diastolic blood pressure levels from baseline to 24 months
Time frame: 24 months
Mean change in LDL cholesterol level from baseline to 24 months
Time frame: 24 months
Mean change in FPG level from baseline to 24 months
Time frame: 24 months
The Summary of Diabetes Self-Care Activities is a scale to measure patients' self-management. The minimum value of each scale item is 0 and the maximum value is 7. Higher scores mean a better outcome.
Time frame: 24 months
Mean change in body mass index (BMI) from baseline to 24 months
Time frame: 24 months
Mean change in waist circumstance (WC) from baseline to 24 months
Time frame: 24 months
Mean change in the European quality of life 5 dimensions 3 levels scale (EQ-5D-3L) index value from baseline to 24 months. The minimum value of the scale is 0 and the maximum value is 1. Higher scores mean a better outcome.
Time frame: 24 months
Mean change in the European quality of life overall self-rated visual analogue scale (EQ-VAS) from baseline to 24 months. The minimum value of the scale is 0 and the maximum value is 100. Higher scores mean a better outcome.
Time frame: 24 months
Pending
Time frame: 24 months
Mean change in urine albumin creatinine ratio (ACR) from baseline to 24 months
Time frame: 24 months
Mean change in estimated glomerular filtration rate (GFR) from baseline to 24 months
The George Institute for Global Health, China
Other
Systematic Medical Assessment, Referral and Treatment for Diabetes Care in China Using Lay Family Health Promoters
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05753436
Cardiovascular Diseases, Diabetes Complications
Cairo, Egypt
View Trial DetailsNCT04161859
Cardiovascular Diseases, Diabetes Mellitus
Pavia, Lombardy, Italy
View Trial DetailsNCT03975556
Abdominal Obesity, Body Weight
San Juan, Puerto Rico
View Trial DetailsNCT01418716
Behavior, Cardiovascular Diseases
Laval, Quebec, Canada
View Trial Details